Multiple Myeloma
Conditions
Interventions
B.breve administered orally three times a day. Continued until three weeks after the start of the chemotherapy two weeks before the start of chemotherapy. Collected blood and stool at 2 weeks before
Sponsors
Department of Hematology. Juntendo University School of medicine.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult patients admitted to the hospital for treatment with auto-PBSCT in order to be diagnosed with multiple myeloma in Department of Hematology Juntendo University School of medicine.
Exclusion criteria
Exclusion criteria: 1.Patient who has a colostomy and gastrostomy. 2.Patient being treated has a collagen disease such as immune dysfunction. 3.Patient being treated has a cranial nerve dysfunction or heart failure during treatment. 4.Patients with more than two weeks, the oral administration of probiotics before the start of this clinical research. 5.Patients not undergoing cryotherapy 6.If the the attending physician has determined inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| bacterial rRNA-targeted reverse transcription-quantitative PCR(BrRNA RT-PCR) | — |
Countries
Japan
Contacts
Public ContactSakurai Hiroko
Juntendo University School of medicine. Department of Hematology.
Outcome results
None listed